Cargando…
Estimating efficacy in trials with selective crossover
When one arm in a trial has a worse early endpoint such as recurrence, a data‐monitoring committee might recommend that all participants are offered the apparently superior treatment. The resultant crossover makes it difficult to measure differences between arms thereafter, including for longer‐term...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485026/ https://www.ncbi.nlm.nih.gov/pubmed/28295486 http://dx.doi.org/10.1002/sim.7275 |